Clinical Efficacy and Immunologic Effects of Omalizumab in Allergic Bronchopulmonary Aspergillosis

Journal of Allergy and Clinical Immunology: In Practice

Volumn 3, Issue 2, 2015, Pages 192-199

  Voskamp, Astrid L ^a,b   Gillman, Andrew ^a   Symons, Karen ^a   Sandrini, Alessandra ^a   Rolland, Jennifer M ^a,b   O'Hehir, Robyn E ^a,b   Douglass, Jo A ^a  

^a ALFRED HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Allergic bronchopulmonary aspergillosis; Basophils; Clinical trial; Omalizumab

Indexed keywords

IMMUNOGLOBULIN E RECEPTOR; NITRIC OXIDE; OMALIZUMAB; PLACEBO; PREDNISOLONE; ANTIALLERGIC AGENT; FUNGUS ANTIGEN; IMMUNOGLOBULIN E;

ADULT; AGED; ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ANAPHYLAXIS; ARTICLE; ASPERGILLUS FUMIGATUS; BASOPHIL; CELL ACTIVATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE EXACERBATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOREACTIVITY; IN VITRO STUDY; MALE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; BLOOD; DRUG EFFECTS; FORCED EXPIRATORY VOLUME; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; AGED; ANTI-ALLERGIC AGENTS; ANTIGENS, FUNGAL; ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; ASPERGILLUS FUMIGATUS; BASOPHILS; CROSS-OVER STUDIES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; IMMUNOGLOBULIN E; MALE; MIDDLE AGED; NITRIC OXIDE; OMALIZUMAB; QUALITY OF LIFE; RECEPTORS, IGE; TREATMENT OUTCOME;

EID: 84924242222     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2014.12.008     Document Type: Article

References (44)

1. Rosenberg M., Patterson R., Mintzer R., Cooper B.J., Roberts M., Harris K.E. Clinical and immunologic criteria for the diagnosis of allergic bronchopulmonary aspergillosis. Ann Intern Med 1977, 86:405-414.
2. Greenberger P.A. Diagnosis and management of allergic bronchopulmonary aspergillosis. Allergy Proc 1994, 15:335-339.
3. Douglass J.A., Sandrini A., Holgate S.T., O'Hehir R.E. Allergic bronchopulmonary aspergillosis and hypersensitivity pneumonitis. Middleton's Allergy Principles and Practice 2013, 1000-1013. Elsevier Saunders, Philadelphia, Pa. 8th ed.
4. Stevens D.A., Schwartz H.J., Lee J.Y., Moskovitz B.L., Jerome D.C., Catanzaro A., et al. Arandomized trial of itraconazole in allergic bronchopulmonary aspergillosis. NEngl J Med 2000, 342:756-762.
5. Wark P.A., Hensley M.J., Saltos N., Boyle M.J., Toneguzzi R.C., Epid G.D., et al. Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomized controlled trial. JAllergy Clin Immunol 2003, 111:952-957.
6. Schwartz H.J., Greenberger P.A. The prevalence of allergic bronchopulmonary aspergillosis in patients with asthma, determined by serologic and radiologic criteria in patients at risk. JLab Clin Med 1991, 117:138-142.
7. Global Strategy for Asthma Management and Prevention. GINA 2011. Accessed 2011. http://www.ginasthma.org/.
8. Chanez P., Contin-Bordes C., Garcia G., Verkindre C., Didier A., De Blay F., et al. Omalizumab-induced decrease of FcxiRI expression in patients with severe allergic asthma. Respir Med 2010, 104:1608-1617.
9. Bousquet J., Cabrera P., Berkman N., Buhl R., Holgate S., Wenzel S., et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005, 60:302-308.
10. Humbert M., Beasley R., Ayres J., Slavin R., Hebert J., Bousquet J., et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005, 60:309-316.
11. Busse W.W., Morgan W.J., Gergen P.J., Mitchell H.E., Gern J.E., Liu A.H., et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. NEngl J Med 2011, 364:1005-1015.
12. Hochhaus G., Brookman L., Fox H., Johnson C., Matthews J., Ren S., et al. Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin 2003, 19:491-498.
13. van der Ent C.K., Hoekstra H., Rijkers G.T. Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody. Thorax 2007, 62:276-277.
14. Lin R.Y., Sethi S., Bhargave G.A. Measured immunoglobulin E in allergic bronchopulmonary aspergillosis treated with omalizumab. JAsthma 2010, 47:942-945.
15. Sastre I., Blanco J., Mata H., Garcia F. Acase of allergic bronchopulmonary aspergillosis treated with omalizumab. JInvestig Allergol Clin Immunol 2012, 22:145-147.
16. Collins J., Devos G., Hudes G., Rosenstreich D. Allergic bronchopulmonary aspergillosis treated successfully for one year with omalizumab. JAsthma Allergy 2012, 5:65-70.
17. Quintas Vazquez L.M., Ortiz Piquer M., Perez de Llano L.A. Effective anti-immunoglobulin-E antibody treatment of a patient with allergic bronchopulmonary aspergillosis. Arch Bronconeumol 2009, 45:207.
18. Tillie-Leblond I., Germaud P., Leroyer C., Tetu L., Girard F., Devouassoux G., et al. Allergic bronchopulmonary aspergillosis and omalizumab. Allergy 2011, 66:1254-1256.
19. Perez-de-Llano L.A., Vennera M.C., Parra A., Guallar J., Marin M., Asensio O., et al. Effects of omalizumab in Aspergillus-associated airway disease. Thorax 2011, 66:539-540.
20. Moss R.B. Treatment options in severe fungal asthma and allergic bronchopulmonary aspergillosis. Eur Respir J 2014, 43:1487-1500.
21. Knol E.F., Mul F.P., Jansen H., Calafat J., Roos D. Monitoring human basophil activation via CD63 monoclonal antibody 435. JAllergy Clin Immunol 1991, 88:328-338.
22. Johansson S.G., Nopp A., van Hage M., Olofsson N., Lundahl J., Wehlin L., et al. Passive IgE-sensitization by blood transfusion. Allergy 2005, 60:1192-1199.
23. Nopp A., Johansson S.G., Ankerst J., Bylin G., Cardell L.O., Gronneberg R., et al. Basophil allergen threshold sensitivity: a useful approach to anti-IgE treatment efficacy evaluation. Allergy 2006, 61:298-302.
24. Nopp A., Cardell L.O., Johansson S.G., Oman H. CD-sens: a biological measure of immunological changes stimulated by ASIT. Allergy 2009, 64:811-814.
25. Eckman J.A., Sterba P.M., Kelly D., Alexander V., Liu M.C., Bochner B.S., et al. Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge. JAllergy Clin Immunol 2010, 125:889-895. e7.
26. Patterson R., Greenberger P.A., Radin R.C., Roberts M. Allergic bronchopulmonary aspergillosis: staging as an aid to management. Ann Intern Med 1982, 96:286-291.
27. Patterson R., Greenberger P.A., Halwig J.M., Liotta J.L., Roberts M. Allergic bronchopulmonary aspergillosis. Natural history and classification of early disease by serologic and roentgenographic studies. Arch Intern Med 1986, 146:916-918.
28. Society A.T. Standardization of Spirometry, 1994 Update. Am J Respir Crit Care Med 1995, 152:29.
29. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 2005, 171:912-930. American Thoracic Society, European Respiratory SocietyEuropean Respiratory Society.
30. Marks G.B., Dunn S.M., Woolcock A.J. Ascale for the measurement of quality of life in adults with asthma. JClin Epidemiol 1992, 45:461-472.
31. Drew A.C., Eusebius N.P., Kenins L., de Silva H.D., Suphioglu C., Rolland J.M., et al. Hypoallergenic variants of the major latex allergen Hev b 6.01 retaining human T lymphocyte reactivity. JImmunol 2004, 173:5872-5879.
32. Schoenhoff M., Bates D., Ruppel J., Fei D., Fox J.A., Thomas D., et al. Pharmacokinetics/dynamics following administration of a recombinant humanized monoclonal anti IgE antibody in the cynomolgus monkey. JAllergy Clin Immunol 1995, 95:356.
33. Lichtenstein L.M., MacGlashan D.W. The concept of basophil releasability. JAllergy Clin Immunol 1986, 77:291-294.
34. Chibana K., Trudeau J.B., Mustovich A.T., Hu H., Zhao J., Balzar S., et al. IL-13 induced increases in nitrite levels are primarily driven by increases in inducible nitric oxide synthase as compared with effects on arginases in human primary bronchial epithelial cells. Clin Exp Allergy 2008, 38:936-946.
35. Hanania N.A., Wenzel S., Rosen K., Hsieh H.J., Mosesova S., Choy D.F., et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 2013, 187:804-811.
36. Tanou K., Zintzaras E., Kaditis A.G. Omalizumab therapy for allergic bronchopulmonary aspergillosis in children with cystic fibrosis: a synthesis of published evidence. Pediatr Pulmonol 2014, 49:503-507.
37. Homma T., Kurokawa M., Matsukura S., Yamaguchi M., Adachi M. Anti-IgE therapy for allergic bronchopulmonary aspergillosis. JMicrobiol Immunol Infect 2013.
38. Stevens D.A., Moss R.B., Kurup V.P., Knutsen A.P., Greenberger P., Judson M.A., et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis-state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003, 37(Suppl 3):S225-S264.
39. Moss R.B. Allergic bronchopulmonary aspergillosis and Aspergillus infection in cystic fibrosis. Curr Opin Pulm Med 2010, 16:598-603.
40. Brinkmann F., Schwerk N., Hansen G., Ballmann M. Steroid dependency despite omalizumab treatment of ABPA in cystic fibrosis. Allergy 2010, 65:134-135.
41. Walker S., Monteil M., Phelan K., Lasserson T.J., Walters E.H. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev 2006, CD003559.
42. Fairs A., Agbetile J., Hargadon B., Bourne M., Monteiro W.R., Brightling C.E., et al. IgE sensitization to Aspergillus fumigatus is associated with reduced lung function in asthma. Am J Respir Crit Care Med 2010, 182:1362-1368.
43. Denning D.W., O'Driscoll B.R., Powell G., Chew F., Atherton G.T., Vyas A., et al. Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: the Fungal Asthma Sensitization Trial (FAST) study. Am J Respir Crit Care Med 2009, 179:11-18.
44. Andersson C.K., Bergqvist A., Mori M., Mauad T., Bjermer L., Erjefalt J.S. Mast cell-associated alveolar inflammation in patients with atopic uncontrolled asthma. JAllergy Clin Immunol 2011, 127:905-912. e1-7.